key: cord-0763339-vinwwfvq
authors: Little, Paul; Francis, Nick A; Stuart, Beth; O'Reilly, Gilly; Thompson, Natalie; Becque, Taeko; Hay, Alastair D; Wang, Kay; Sharland, Michael; Harnden, Anthony; Yao, Guiqing; Raftery, James; Zhu, Shihua; Little, Joseph; Hookham, Charlotte; Rowley, Kate; Euden, Joanne; Harman, Kim; Coenen, Samuel; Read, Robert C; Woods, Catherine; Butler, Christopher C; Faust, Saul N; Leydon, Geraldine; Wan, Mandy; Hood, Kerenza; Whitehurst, Jane; Richards-Hall, Samantha; Smith, Peter; Thomas, Michael; Moore, Michael; Verheij, Theo
title: Antibiotics for lower respiratory tract infection in children presenting in primary care in England (ARTIC PC): a double-blind, randomised, placebo-controlled trial
date: 2021-10-16
journal: Lancet
DOI: 10.1016/s0140-6736(21)01431-8
sha: 132df47fa96fcccdea2e786f871e55bc2425d470
doc_id: 763339
cord_uid: vinwwfvq

BACKGROUND: Antibiotic resistance is a global public health threat. Antibiotics are very commonly prescribed for children presenting with uncomplicated lower respiratory tract infections (LRTIs), but there is little evidence from randomised controlled trials of the effectiveness of antibiotics, both overall or among key clinical subgroups. In ARTIC PC, we assessed whether amoxicillin reduces the duration of moderately bad symptoms in children presenting with uncomplicated (non-pneumonic) LRTI in primary care, overall and in key clinical subgroups. METHODS: ARTIC PC was a double-blind, randomised, placebo-controlled trial done at 56 general practices in England. Eligible children were those aged 6 months to 12 years presenting in primary care with acute uncomplicated LRTI judged to be infective in origin, where pneumonia was not suspected clinically, with symptoms for less than 21 days. Patients were randomly assigned in a 1:1 ratio to receive amoxicillin 50 mg/kg per day or placebo oral suspension, in three divided doses orally for 7 days. Patients and investigators were masked to treatment assignment. The primary outcome was the duration of symptoms rated moderately bad or worse (measured using a validated diary) for up to 28 days or until symptoms resolved. The primary outcome and safety were assessed in the intention-to-treat population. The trial is registered with the ISRCTN Registry (ISRCTN79914298). FINDINGS: Between Nov 9, 2016, and March 17, 2020, 432 children (not including six who withdrew permission for use of their data after randomisation) were randomly assigned to the antibiotics group (n=221) or the placebo group (n=211). Complete data for symptom duration were available for 317 (73%) patients; missing data were imputed for the primary analysis. Median durations of moderately bad or worse symptoms were similar between the groups (5 days [IQR 4–11] in the antibiotics group vs 6 days [4–15] in the placebo group; hazard ratio [HR] 1·13 [95% CI 0·90–1·42]). No differences were seen for the primary outcome between the treatment groups in the five prespecified clinical subgroups (patients with chest signs, fever, physician rating of unwell, sputum or chest rattle, and short of breath). Estimates from complete-case analysis and a per-protocol analysis were similar to the imputed data analysis. INTERPRETATION: Amoxicillin for uncomplicated chest infections in children is unlikely to be clinically effective either overall or for key subgroups in whom antibiotics are commonly prescribed. Unless pneumonia is suspected, clinicians should provide safety-netting advice but not prescribe antibiotics for most children presenting with chest infections. FUNDING: National Institute for Health Research.

1 Appendix. High risk 0/6 (0.0%) 0/4 (0.0%)

Among those who reported adherence, most (95%) started taking their medication on day 1, adherence was maintained in the antibiotics arm over days 1 to 5, but decreased gradually to 84% by day 5 in the placebo arm. Reported adherence was higher for longer prior duration of illness (OR 1.08, 95% CI 1.01 to 1.16) adjusting for group and other prespecified covariates. Among those who thought their child was receiving antibiotics, 68 (85%) adhered to their medication, and among those who thought their child was receiving placebo 82 (82%) adhered to their medication. There was little evidence for clustering by GP practice, intracluster correlation ICC 0.01 (95% CI 0.00 to 0.99).

In order to provide a lower bound to the adherence, we assume that all those who completed the diary but did not fill in medication dosage did not adhere to their medication. Under this assumption, 98/161 (60.9%) in the Antibiotics group and 87/156 (55.8%) in the Placebo group adhered to their medication. In order to provide an upper bound to the adherence, we assume all those who completed the diary but did not fill in medication dosage did adhere. Under this assumption, adherence was 140/161 (87.0%) in the antibiotics arm and 130/156 (83.3%) in the placebo arm. If adherence is low, the ITT effect of antibiotics on duration will be diluted. Therefore, as a sensitivity analysis, assuming all those who completed the diary but did not fill in medication dosage did not adhere in the antibiotics arm. High risk 9 -*** ---*Adjusted for prior duration of illness, baseline severity, age, and comorbidity; **95% CI for the abnormal chest signs subgroup. ***too few data to obtain reliable estimates High risk 9 ***----*Adjusted for prior duration of illness, baseline severity, age, comorbidity, and all other subgroups; **95% CI for the abnormal chest signs subgroup. ***too few data to obtain reliable estimates Yes 57 6 (4, 5) 57 4 (3, 10) -1 (-6.8, 4.8) -2 (-6.6, 2.6) -1.2 (-7.6, 5.1) -1.8 (-7.5, 3.8) No 54 7 (4, 17) 61 6 (4,10) -1 (-5.5, 3.5) -0.6 (-5.3, 4.0) *Adjusted for age, baseline severity, comorbidity and prior duration of illness 

Number of times had cough in last 12 months

Prior influenza vaccine in last 12 months

Prior pneumococcal vaccine (booster) in last 12 months

Search Strategy for Cochrane Systematic review:The authors searched for primary research of randomised controlled trials with no language restrictions in CENTRAL 2016, Issue 11 (accessed 13 January 2017), MEDLINE (1966 to January week 1, 2017 ), Embase (1974 to 13 January 2017 ), and LILACS (1982 to 13 January 2017 ; andsearched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov on 5 April 2017. The search terms used were: 1 exp Bronchitis/ 2 bronchit*.tw. 3 (bronchial adj2 infect*).tw. 4 exp Respiratory Tract Infections/ 5 or/1-4 6 exp Anti-Bacterial Agents/ 7 exp Lactams/ 8 exp Tetracyclines/ 9 exp Aminoglycosides/ 10 exp Glycopeptides/ 11 exp Macrolides/ 12 antibiotic*.tw. 13 (alamethicin or amdinocillin* or amikacin or amoxicillin* or ampicillin or aurodox or azithromycin or azlocillin or aztreonam or bacitracin or bacteriocin* or brefeldin* or butirosin* or candicidin or carbenicillin or carfecillin or cefaclor or cefadroxil or cefamandole or cefazolin or cefixime or cefmenoxime or cefmetazole or cefonicid or cefoperazone or cefotaxime or cefotetan or cefotiam or cefoxitin or cefsulodin or ceftazidime or ceftizoxime or ceftriaxone or cefuroxime or cephacetrile or cephalexin or cephaloglycin or cephaloridine or cephalosporin* or cephalothin or cephapirin or cephradine or chloramphenicol or chlortetracycline or citrinin or clarithromycin or clavulanic acid* or clindamycin or cloxacillin or colistin or cyclacillin or dactinomycin or daptomycin or demeclocycline or dibekacin or dicloxacillin or dihydrostreptomycin* or distamycin* or doxycycline or echinomycin or edeine or erythromycin* or floxacillin or framycetin or fusidic acid or gentamicin* or gramicidin or imipenem or lactam* or lasalocid or leucomycins or lymecycline or mepartricin or methacycline or methicillin or mezlocillin or mikamycin or minocycline or miocamycin or moxalactam or mupirocin or mycobacillin or nafcillin or nebramycin or enigericin or nisin or novobiocin or nystatin or ofloxacin or oligomycins or oxacillin or oxytetracycline or penicillanic acid or penicillic acid or penicillin* or piperacillin or pivampicillin or polymyxin* or pristinamycin* or prodigiosin or rifabutin or ristocetin or rolitetracycline or roxarsone or rutamycin or sirolimus or sisomicin or spectinomycin or streptogramin* or streptovaricin or sulbactam or sulbenicillin or talampicillin or teicoplanin or tetracycline or thiamphenicol or thiostrepton or ticarcillin or tobramycin or troleandomycin or tylosin or tyrocidine or tyrothricin or valinomycin or vancomycin or vernamycin* or viomycin* or virginiamycin* or beta-lactam*).tw,nm. 14 or/6-13 15 5 and 14 The MEDLINE search was combined with the Cochrane Highly Sensitive Strategy for identifying randomised trials in MEDLINE: sensitivity-and precision-maximising version (2008 revision); Ovid format (Lefebvre 2011).